396 related articles for article (PubMed ID: 25634992)
1. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA; Johnstone MR; Lahiri SD
J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
[TBL] [Abstract][Full Text] [Related]
2. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
3. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
Livermore DM; Mushtaq S; Vickers A; Woodford N
Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
[TBL] [Abstract][Full Text] [Related]
4. Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested
Zhang Y; Kashikar A; Brown CA; Denys G; Bush K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559260
[TBL] [Abstract][Full Text] [Related]
5. Identification of Mutations in the
Ranjitkar S; Reck F; Ke X; Zhu Q; McEnroe G; Lopez SL; Dean CR
mSphere; 2019 Jul; 4(4):. PubMed ID: 31270174
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Le Terrier C; Nordmann P; Sadek M; Poirel L
J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
Estabrook M; Kazmierczak KM; Wise M; Arhin FF; Stone GG; Sahm DF
J Glob Antimicrob Resist; 2021 Mar; 24():316-320. PubMed ID: 33524556
[TBL] [Abstract][Full Text] [Related]
8. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
9. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
Sadek M; Juhas M; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
[TBL] [Abstract][Full Text] [Related]
10.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
11. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids.
Ma K; Feng Y; Zong Z
Int J Antimicrob Agents; 2022 Sep; 60(3):106642. PubMed ID: 35872296
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
[TBL] [Abstract][Full Text] [Related]
15.
Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
[TBL] [Abstract][Full Text] [Related]
20. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
